PMID- 33293815
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220418
IS  - 1176-6328 (Print)
IS  - 1178-2021 (Electronic)
IS  - 1176-6328 (Linking)
VI  - 16
DP  - 2020
TI  - Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality 
      of Life and Burden.
PG  - 2899-2912
LID - 10.2147/NDT.S256217 [doi]
AB  - PURPOSE: The aim of this study was to assess the burden and the quality of life 
      (QoL) perceived by caregivers assisting advanced Parkinson's disease (PD) 
      patients. PATIENTS AND METHODS: Consecutive advanced PD patients treated with 
      levodopa/carbidopa intestinal gel (LCIG) or continuous subcutaneous apomorphine 
      infusion (CSAI) or care as usual (CU) and their care partners were recruited 
      during routine visits according to a cross-sectional design. Caregiver's distress 
      was assessed by Zarit Burden Interview (ZBI) and a QoL survey to evaluate and 
      understand the burden experienced by care partners during family and working 
      activities. RESULTS: A total of 126 patients (53 LCIG, 19 CSAI and 54 CU) and 
      their care partners were enrolled. The ZBI score boxplot showed that LCIG and CU 
      populations have a similar distribution (ZBI inter-quartile range [IQR] values 
      respectively 18-42 for LCIG and 19-43 for CU group), while the CSAI group has a 
      wider score range (IQR 16-52). Caregivers assisting patients in treatment with 
      LCIG have more time to perform family or household duties (p=0.0022), or to 
      engage in leisure activities (p=0.0073) compared to CU, while no difference was 
      found when compared to CSAI group. Approximately 50% of the care partners showed 
      mood changes in the last 6 months and LCIG and CSAI had less impact on 
      caregiver's mood compared to CU. Patients treated with LCIG were more independent 
      in taking a bath or shower without assistance and were more able to move and walk 
      without assistance. CONCLUSION: Care partners of advanced PD patients treated 
      with device-aided therapies have more time for their own life and a better 
      perception of their QoL with a tendency to an improvement of mood compared with 
      those of patients treated with CU.
CI  - (c) 2020 Modugno et al.
FAU - Modugno, Nicola
AU  - Modugno N
AUID- ORCID: 0000-0001-5243-1775
AD  - Neurology Unit, IRCCS Neuromed, Pozzilli, Italy.
FAU - Antonini, Angelo
AU  - Antonini A
AUID- ORCID: 0000-0003-1040-2807
AD  - Parkinson and Movement Disorder Unit, Department of Neuroscience, University of 
      Padua, Padua, Italy.
FAU - Tessitore, Alessandro
AU  - Tessitore A
AD  - Department of Medical and Surgery Sciences, University of Campania, "Luigi 
      Vanvitelli", Naples, Italy.
FAU - Marano, Pietro
AU  - Marano P
AD  - Casa di Cura Madonna del Rosario, Raggruppamento di Riabilitazione, Catania, 
      Italy.
FAU - Pontieri, Francesco Ernesto
AU  - Pontieri FE
AD  - Department NESMOS, "Sapienza" University, Sant'Andrea Hospital, Roma, Italy.
AD  - IRCCS Fondazione Santa Lucia, Roma, Italy.
FAU - Tambasco, Nicola
AU  - Tambasco N
AUID- ORCID: 0000-0003-1497-4482
AD  - Department of Neurology, Perugia General Hospital and University of Perugia, 
      Perugia, Italy.
FAU - Canesi, Margherita
AU  - Canesi M
AD  - Dipartimento di Riabilitazione Malattia di Parkinson e Disordini del Movimento, 
      Gravi Cerebrolesioni Acquisite, Italia Hospital - Ospedale "Moriggia-Pelascini", 
      Gravedona ed Uniti, Como, Italy.
AD  - Centro Parkinson e Disordini del Movimento, CTO, G Pini, Milano, Italy.
FAU - Fabbrini, Giovanni
AU  - Fabbrini G
AUID- ORCID: 0000-0001-7614-8771
AD  - Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
AD  - IRCCS Neuromed, Pozzilli, Isernia, Italy.
FAU - Sensi, Mariachiara
AU  - Sensi M
AD  - Neurology Unit, Hospital Sant'Anna, Ferrara, Italy.
FAU - Quatrale, Rocco
AU  - Quatrale R
AD  - Neurology Unit, Hospital dell'Angelo, Mestre, VE, Italy.
FAU - Solla, Paolo
AU  - Solla P
AD  - Neurology Unit, Policlinico Universitario Monserrato, Cagliari, Italy.
FAU - Defazio, Giovanni
AU  - Defazio G
AD  - Neurology Unit, Policlinico Universitario Monserrato, Cagliari, Italy.
FAU - Melzi, Gabriella
AU  - Melzi G
AD  - Medical Department, AbbVie Srl, Roma, Italy.
FAU - Gualberti, Giuliana
AU  - Gualberti G
AUID- ORCID: 0000-0003-4120-2621
AD  - Medical Department, AbbVie Srl, Roma, Italy.
FAU - Lopiano, Leonardo
AU  - Lopiano L
AUID- ORCID: 0000-0001-9098-387X
AD  - Department of Neuroscience "Rita Levi Montalcini" University of Torino, Azienda 
      Ospedaliero-Universitaria Citta Della Salute e Della Scienza di Torino, Torino, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20201202
PL  - New Zealand
TA  - Neuropsychiatr Dis Treat
JT  - Neuropsychiatric disease and treatment
JID - 101240304
EIN - Neuropsychiatr Dis Treat. 2021 Jan 13;17:67-68. PMID: 33469293
PMC - PMC7719333
OTO - NOTNLM
OT  - advanced Parkinson's disease
OT  - caregiver burden
OT  - intestinal infusion
OT  - levodopa/carbidopa
OT  - quality of life; QoL
COIS- N. Modugno reports fees for oral presentations from AbbVie, UCB, Zambon and Bial. 
      A. Antonini has received compensation for consultancy and speaker related 
      activities from UCB, Boehringer Ingelheim, AbbVie, Zambon, Bial, Ever Pharma, 
      Neuroderm, Therevance, Biogen; he receives research support from Chiesi 
      Pharmaceuticals, Lundbeck, Horizon 2020 - PD_Pal Grant 825,785, Ministry of 
      Education University and Research (MIUR) Grant ARS01_01081. He serves as 
      consultant for Boehringer-Ingelheim for legal cases on pathological gambling". A. 
      Tessitore declares speaking honoraria and travel expenses for attending meetings 
      from AbbVie. P. Marano declares consultancy fees from AbbVie. F.E. Pontieri 
      received honoraria for speaker activity from Zambon, AbbVie, Bial, compensation 
      for serving in the Steering Committee of an international grant from AbbVie; he 
      also received an unconditioned grant for research activity from Zambon. N. 
      Tambasco received speaker honoraria from Lundbeck and AbbVie. M. Canesi declares 
      grants from UCB, Zambon and Ralpharma. G. Fabbrini received payment for 
      International Congress from Zambon; he is also the editorial board for 
      Parkinsonism and Related Disorders. R. Quatrale has received honoraria for 
      consulting services and symposia from AbbVie and Zambon. P. Solla has received 
      honoraria for participation in advisory boards from AbbVie. G. Gualberti, G. 
      Melzi, are employees of AbbVie Italy and may own AbbVie stocks/options. The other 
      authors report no conflicts of interest in this work.
EDAT- 2020/12/10 06:00
MHDA- 2020/12/10 06:01
PMCR- 2020/12/02
CRDT- 2020/12/09 06:12
PHST- 2020/04/04 00:00 [received]
PHST- 2020/10/01 00:00 [accepted]
PHST- 2020/12/09 06:12 [entrez]
PHST- 2020/12/10 06:00 [pubmed]
PHST- 2020/12/10 06:01 [medline]
PHST- 2020/12/02 00:00 [pmc-release]
AID - 256217 [pii]
AID - 10.2147/NDT.S256217 [doi]
PST - epublish
SO  - Neuropsychiatr Dis Treat. 2020 Dec 2;16:2899-2912. doi: 10.2147/NDT.S256217. 
      eCollection 2020.